Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31571073 | 1.00 | GRM1 (0.40) | GRM1CYP17A1CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL8060208 | 0.90 | GRM1 (0.41) | GRM1ALDH1A1KDM4EL3MBTL1AKR1C3 | |
| SCHEMBL31571076 | 0.90 | GRM1 (0.41) | GRM1ALDH1A1KDM4EL3MBTL1AKR1C3 | |
| SCHEMBL8156954 | 0.86 | GRM1 (0.40) | GRM1ALDH1A1KDM4EL3MBTL1AKR1C3 | |
| SCHEMBL8153599 | 0.84 | LTB4R (0.42) | GRM1CYP2C9CYP2C19ALDH1A1KDM4E | |
| SCHEMBL13230062 | 0.83 | GRM1 (0.38) | GRM1L3MBTL1PPARG | |
| SCHEMBL8154310 | 0.82 | GRM1 (0.45) | GRM1ALDH1A1KDM4EL3MBTL1GFER | |
| SCHEMBL8064614 | 0.81 | CYP17A1 (0.38) | CYP17A1CYP2C9CYP2C19AKR1C3AKR1C2 | |
| SCHEMBL8154980 | 0.81 | GRM1 (0.39) | GRM1ALDH1A1KDM4EL3MBTL1GFER | |
| SCHEMBL12894106 | 0.78 | GRM1 (0.46) | GRM1AKR1C3AKR1C2PTGS1AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101892-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated (US) | 2025-05-15 | — | — | WO | disclosed |
| US-8404713-B2 | Quinolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-26 | — | — | US | disclosed |
| US-8404713-B2 | Quinolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-26 | — | — | US | disclosed |
| US-20100222348-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222348-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-02 | — | — | US | disclosed |
| WO-2009053373-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222348-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP11 | GRM1 3148/4885CYP17A1 2192/4885CYP2C9 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.